Stability indicating RP-HPLC method for the simultaneous estimation of olaparib & bevacizumab in pharmaceutical dosage forms

Olaparib and Bevacizumab are anti-cancer agents. A new stability indicating RP-HPLC technique has been developed and validated for the simultaneous assay of Olaparib and Bevacizumab using Inertsil ODS column with UV detection at 258 nm within a run time of 6 minutes where Olaparib was eluted at 2.336 min and that of Bevacizumab at 4.873 min. Linearity was observed over the concentration range 37.50-225 μg/mL for Olaparib and 6.25-37.50 μg/mL for Bevacizumab respectively and the regression equations were found to be y=16815.19x+22410.75 and y=14512.58x+2387.04 for Olaparib and Bevacizumab respectively. The LOD was found to be 0.9 μg/ml and 0.1500 μg/mL whereas the LOQ was found to be 3.00 μg/mL and 0.5000 μg/mL for Olaparib and Bevacizumab respectively.